AU6860901A - Enhanced brain function by gaba-ergic stimulation - Google Patents

Enhanced brain function by gaba-ergic stimulation

Info

Publication number
AU6860901A
AU6860901A AU6860901A AU6860901A AU6860901A AU 6860901 A AU6860901 A AU 6860901A AU 6860901 A AU6860901 A AU 6860901A AU 6860901 A AU6860901 A AU 6860901A AU 6860901 A AU6860901 A AU 6860901A
Authority
AU
Australia
Prior art keywords
ergic
gaba
stimulation
brain function
enhanced brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6860901A
Inventor
Audie G Leventhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Publication of AU6860901A publication Critical patent/AU6860901A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU6860901A 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation Pending AU6860901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21338800P 2000-06-23 2000-06-23
US27742701P 2001-03-20 2001-03-20
PCT/US2001/019719 WO2002000221A1 (en) 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation

Publications (1)

Publication Number Publication Date
AU6860901A true AU6860901A (en) 2002-01-08

Family

ID=26908032

Family Applications (3)

Application Number Title Priority Date Filing Date
AU6860901A Pending AU6860901A (en) 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation
AU2001268609A Ceased AU2001268609B2 (en) 2000-06-23 2001-06-20 Enhanced brain function by GABA-ergic stimulation
AU2006203432A Abandoned AU2006203432A1 (en) 2000-06-23 2006-08-09 Enhanced brain function by GABA-ergic stimulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001268609A Ceased AU2001268609B2 (en) 2000-06-23 2001-06-20 Enhanced brain function by GABA-ergic stimulation
AU2006203432A Abandoned AU2006203432A1 (en) 2000-06-23 2006-08-09 Enhanced brain function by GABA-ergic stimulation

Country Status (4)

Country Link
EP (1) EP1303280A4 (en)
AU (3) AU6860901A (en)
CA (1) CA2413405A1 (en)
WO (1) WO2002000221A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016329A1 (en) * 2007-07-31 2009-02-05 Cambridge Enterprise Limited Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3397209A (en) * 1966-11-25 1968-08-13 Geigy Chem Corp 3-hydroxy-5-isoxazole-carboxamide
US5958933A (en) * 1982-11-23 1999-09-28 Naftchi; N. Eric Neurologically active compounds and compounds with multiple activities
GB9812038D0 (en) * 1998-06-04 1998-07-29 Merck Sharp & Dohme Therapeutic compound
WO2000027382A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
WO2000027849A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands

Also Published As

Publication number Publication date
EP1303280A4 (en) 2005-09-21
EP1303280A1 (en) 2003-04-23
WO2002000221B1 (en) 2002-02-28
CA2413405A1 (en) 2002-01-03
AU2006203432A1 (en) 2006-08-31
AU2001268609B2 (en) 2006-05-11
WO2002000221A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
GB0028264D0 (en) Well treatment
GB0028269D0 (en) Well treatment
EP1425066A4 (en) Defibrillators
GB0028429D0 (en) Therapy
PL362855A1 (en) Improved treatment
GB0003556D0 (en) Cochlear implant
GB0030583D0 (en) Nerve regeneration
GB2358194B (en) Electrolytic treatment
GB2379395B (en) Cardiac stimulation apparatus
GB0001710D0 (en) Therapeutic treatment
EP1427478A4 (en) Defibrillators
GB0122746D0 (en) Defibrillator
AU6860901A (en) Enhanced brain function by gaba-ergic stimulation
AU2096002A (en) Therapeutic treatment
EP1279384A4 (en) Erogenic zone stimulator
GB0031321D0 (en) Treatment
GB0014437D0 (en) Immune response stimulation
GB0207931D0 (en) Brain stimulator
GB2405099B (en) Cardiac stimulation apparatus
GB0014548D0 (en) Boiler brain
GB0009482D0 (en) Baby controlled stimulation system
GB0006471D0 (en) Foetal stimulator
CA89815S (en) Electro-medical nerve stimulation apparatus
GB0111047D0 (en) Pacemaker
GB0107878D0 (en) Pacemaker